跳至主要内容
临床试验/NCT03017430
NCT03017430已完成4 期

Randomized Clinical Trial of Pregabalin for Opioid Withdrawal Syndrome

St. Petersburg Bekhterev Research Psychoneurological Institute1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
Number of patients completed detoxification

研究概览

简要总结

It is a single blind randomized symptom triggered study to assess efficacy and safety of pregablin combined with the symptom triggered treatment for opiate withdrawal syndrome vs. clonidne with the same with the symptom triggered treatment for opiate withdrawal syndrome.

详细描述

Study design: Single-blind randomized symptom-regulated protocol with an active control. Eighty patients admitted to an inpatient addiction treatment program will be randomly assigned to two groups. The first group (N=40) receives up to 600 mg a day of Pregabalin for six days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine). The second group (N= 40) receives up to 600 micrograms of Clonidine a day as the main treatment along with the same basic and symptomatic regimen. Opiate withdrawal severity, craving, sleep disturbance, anxiety and depression, as well as general clinical impressions and side effects are assessed daily by psychiatrists who are blind to patients' group assignment using internationally validated quantitative psychometric instruments.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
20 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Opioid Use Disorders; Opioid Withdrawal Syndrome

排除标准

  • Severe psychiatric and somatic disorders, other Substance Use Disorders (except tobacco)

研究组 & 干预措施

Pregabalin

Experimental

This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).

干预措施: Pregabalin (Drug)

Pregabalin

Experimental

This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).

干预措施: Doxylamin (Drug)

Pregabalin

Experimental

This group (N= 40) receives up to 600 mg a day of Pregabalin for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).

干预措施: Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine) (Drug)

Clonidine

Active Comparator

This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..

干预措施: Clonidine (Drug)

Clonidine

Active Comparator

This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..

干预措施: Doxylamin (Drug)

Clonidine

Active Comparator

This group (N= 40) receives up to 600 micrograms of Clonidine a day for six-seven days along with symptomatic therapy that is divided into basic treatment that is given to all patients (Doxylamin 30 mg/day) and additional medications based on patients' needs as determined by a psychiatrist using the Opioid Withdrawal Scale and included Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)..

干预措施: Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine) (Drug)

结局指标

主要结局

Number of patients completed detoxification

时间窗: 7 days

Compares number of patients that finish treatment of opioid withdrawal syndrome (detoxification) in two treatment arms.

次要结局

  • Amount of Ketorolac administered(7 days)
  • Number and severity of adverse events(7 days)
  • Severity of opiod withdrawal(7 days)

研究者

发起方
St. Petersburg Bekhterev Research Psychoneurological Institute
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验